Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2020

01-01-2020 | Breast Cancer | Clinical trial

Long-term prognostic effect of hormone receptor subtype on breast cancer

Authors: Ki-Tae Hwang, Jongjin Kim, Jiwoong Jung, Byoung Hyuck Kim, Jeong Hwan Park, Sook Young Jeon, Kyu Ri Hwang, Eun Youn Roh, Jin Hyun Park, Su-jin Kim

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Login to get access

Abstract

Purpose

To determine the long-term prognostic role of hormone receptor subtype in breast cancer using surveillance, epidemiology, and end results (SEER) database.

Methods

Data of 810,587 female operable invasive breast cancer patients from SEER database with a mean follow-up period of 94.2 months (range, 0–311 months) were analyzed. Hormone receptor subtype was classified into four groups based on estrogen receptor (ER) and progesterone receptor (PR) statuses: ER(+)/PR(+), ER(+)/PR(−), ER(−)/PR(+), and ER(−)/PR(−).

Results

Numbers of subjects with ER(+)/PR(+), ER(+)/PR(−), ER(−)/PR(+), ER(−)/PR(−), and unknown were 496,279 (61.2%), 86,858 (10.7%), 11,545 (1.4%), 135,441 (16.7%), and 80,464 (9.9%), respectively. The ER(+)/PR(+) subtype showed the best breast-cancer-specific survival, followed by ER(+)/PR(−), ER(−)/PR(+), and ER(−)/PR(−) subtypes in the respective order (all p < 0.001). Survival difference among hormone receptor subtypes was maintained in subgroup analysis according to anatomic stage, race, age group, and year of diagnosis. Hormone receptor subtype was a significant independent prognostic factor in multivariable analyses (p < 0.001). Hazard ratios of ER(+)/PR(−), ER(−)/PR(+), and ER(−)/PR(−) for breast-cancer-specific mortality risk were 1.419 (95% confidence interval [CI] 1.383–1.456), 1.630 (95% CI 1.537–1.729), and 1.811 (95% CI 1.773–1.848), respectively, with ER(+)/PR(+) as reference.

Conclusion

Hormone receptor subtype is a significant independent prognostic factor in female operable invasive breast cancer patients with long-term effect. The ER(+)/PR(+) subtype shows the most favorable prognosis, followed by ER(+)/PR(−), ER(−)/PR(+), and ER(−)/PR(−) subtypes in the respective order. Prognostic impacts of hormone receptor subtypes are also maintained in subgroup analysis according to anatomic stage, race, age, and year of diagnosis.
Appendix
Available only for authorised users
Literature
1.
Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF et al (2018) Global, regional, and National Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer Groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4:1553–1568CrossRef
2.
Hwang KT, Kim J, Jung J et al (2019) Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res 25:1970–1979PubMed
3.
NCCN Guidelines for breast cancer, Version 4.2018, released on Feb 8th, 2019. (https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​breast.​pdf), access date: 10 Feb 2019
4.
Burstein HJ, Lacchetti C, Anderson H et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423–438CrossRef
5.
Curigliano G, Burstein HJ, Winer EP et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017. Ann Oncol 28(8):1700–1712CrossRef
6.
Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795CrossRef
7.
Rakha EA, El-Sayed ME, Green AR et al (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772–4778CrossRef
8.
Schroth W, Winter S, Buttner F et al (2016) Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. Breast Cancer Res Treat 155:85–97CrossRef
9.
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979CrossRef
10.
Grann VR, Troxel AB, Zojwalla NJ et al (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241–2251CrossRef
11.
Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6CrossRef
12.
Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 15:593–602CrossRef
13.
Bae SY, Kim S, Lee JH et al (2015) Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 15:138CrossRef
14.
Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD (2000) Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53:688–696CrossRef
15.
Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261CrossRef
16.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRef
17.
Olivotto IA, Truong PT, Speers CH et al (2004) Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22:1769–1770CrossRef
18.
De Maeyer L, Van Limbergen E, De Nys K et al (2008) Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26(2):335–336CrossRef
19.
Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am J Clin Pathol 123:21–27CrossRef
20.
Foley NM, Coll JM, Lowery AJ et al (2018) Re-appraisal of estrogen receptor negative/progesterone receptor positive (ER −/PR +) breast cancer phenotype: true subtype or technical artefact? Pathol Oncol Res 24:881–884CrossRef
21.
Rhodes A, Jasani B (2009) The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol 62:95–96CrossRef
22.
Creighton CJ, Kent Osborne C, van de Vijver MJ et al (2009) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114:287–299CrossRef
23.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721–7735CrossRef
24.
Park S, Park BW, Kim TH et al (2013) Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. Ann Surg Oncol 20:1505–1513CrossRef
25.
Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than 5 years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690CrossRef
26.
Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846CrossRef
27.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRef
28.
Fisher ER, Anderson S, Dean S et al (2005) Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103:164–173CrossRef
29.
Hefti MM, Hu R, Knoblauch NW et al (2013) Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 15:R68CrossRef
30.
Banerjee M, George J, Song EY, Roy A, Hryniuk W (2004) Tree-based model for breast cancer prognostication. J Clin Oncol 22:2567–2575CrossRef
31.
Ponzone R, Montemurro F, Maggiorotto F et al (2006) Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 17:1631–1636CrossRef
32.
Liu S, Chia SK, Mehl E et al (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119:53–61CrossRef
33.
Braun L, Mietzsch F, Seibold P et al (2013) Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. Mod Pathol 26:1161–1171CrossRef
34.
Van Asten K, Slembrouck L, Olbrecht S et al (2019) Prognostic value of the progesterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer. Oncologist 24:165–171CrossRef
35.
Vaz-Luis I, Ottesen RA, Hughes ME et al (2012) Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 14:R129CrossRef
36.
Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51:227–238CrossRef
37.
Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227–237CrossRef
38.
Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065CrossRef
39.
Liao GS, Dai MS, Hsu HM et al (2017) Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer. Eur J Surg Oncol 43:1855–1861CrossRef
Metadata
Title
Long-term prognostic effect of hormone receptor subtype on breast cancer
Authors
Ki-Tae Hwang
Jongjin Kim
Jiwoong Jung
Byoung Hyuck Kim
Jeong Hwan Park
Sook Young Jeon
Kyu Ri Hwang
Eun Youn Roh
Jin Hyun Park
Su-jin Kim
Publication date
01-01-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05456-w

Other articles of this Issue 1/2020

Breast Cancer Research and Treatment 1/2020 Go to the issue

Preclinical study

Prevalence and scope of advanced practice provider oncology care among Medicare beneficiaries with breast cancer

Epidemiology

Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study

Preclinical study

Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort

Clinical trial

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

Epidemiology

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Brief Report

Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits